Stock Ratings / Health Care / XTLB / options

NCNA (56) DRMA (43) AZTR (41) MDCX (35) ⌘ Pro Terminal →

XTL Biopharmaceuticals Ltd. (XTLB) Options Positioning, Max Pain & Unusual Sweeps

$1.76 -12.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

XTL Biopharmaceuticals Ltd. (XTLB) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $4.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XTLB)Realized 20D OHLCV Swing Band: ±12.3%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.3%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (XTLB)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for XTLB.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XTLB)

✓Walkthrough of XTLB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XTLB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.87%▼ SUPPORT BREAKDOWN

2026-10-30O $1.65H $1.76L $1.60C $1.76VOL 8.6K

RES: $3.67SUP: $2.25SMA50: $2.23SMA200: $2.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XTLB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XTLB Butterfly Map → + Track XTLB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XTLB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XTLB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XTLB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XTLB)

Health Care Rank #431 of 1016 ⚔️ NCNA vs XTLB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XTLB vs. NCNA, DRMA, AZTR, MDCX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, XTL Biopharmaceuticals Ltd. (XTLB) ranks #431 by composite RQD confidence (47/100, grade D) and #957 by equity capitalization ($4.3M). Within this direct 5-issuer industry benchmark cohort, XTLB leads on earnings valuation at N/A trailing P/E, while DRMA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NCNA currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with XTLB at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XTLB ACTIVE XTL Biopharmaceuticals Ltd.	D	47/100	—	—	—	-12.44%	$4.3M	Benchmark Subject
NCNA NuCana plc	D+	56/100	—	—	—	-3.26%	$4.3M	/ncna-vs-xtlb →
DRMA Dermata Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.84%	$4.2M	/drma-vs-xtlb →
AZTR Azitra Inc	D-	41/100	—	—	-35.0%	-16.31%	$4.6M	/aztr-vs-xtlb →
MDCX Medicus Pharma Ltd.	D-	35/100	—	—	-35.0%	-13.31%	$4.1M	/mdcx-vs-xtlb →

2. XTLB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

XTL Biopharmaceuticals Ltd. (XTLB) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. XTLB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XTLB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.76 (-12.44% 1D, market cap $4.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XTLB ranks #431 in composite RQD confidence.

How does XTLB compare to NCNA and DRMA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XTLB carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NCNA (NuCana plc) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $4.3M) and DRMA (Dermata Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, XTLB leads on earnings multiple (N/A) while DRMA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XTLB?

For XTL Biopharmaceuticals Ltd. (XTLB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #431 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XTLB trading relative to its 50-day, 200-day, and 52-week technical levels?

XTLB last traded at $1.76 (-12.44% on volume of 7,065 shares), positioning the stock -21.08% below its 50-day simple moving average ($2.23) and -35.06% below its 200-day simple moving average ($2.71). Across its 52-week range of $1.60 to $5.64, XTLB sits at the 4.0% percentile with a 14-day RSI of 33.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($1.54 to $1.98).

XTLB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is XTLB's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for XTLB.

Direct Sub-Reports: XTLB RQD Cockpit XTLB 12M Forecast XTLB Earnings & Move XTLB Dividends & DRIP XTLB Insiders & 13F XTLB Whale Options XTLB Profit Sankey XTLB News & Why